Full Press Release Details
Alcon Affiliate Receives
Generic Glaucoma Medication
Worth, Texas Sept. 16, 2003 The U.S. Food and Drug Administration today
approved Falcon Pharmaceuticals, Ltd. s (Falcon) generic brimonidine tartrate
ophthalmic solution 0.2% (brimonidine). Falcon is an affiliate of Alcon, Inc. (NYSE:ACL),
the world s leading eye care company. Brimonidine is therapeutically equivalent to
Alphagan* and is indicated for lowering intraocular pressure in patients with open-angle
glaucoma or ocular hypertension. The drug is available immediately, and comes in a
Drop-tainer** dispenser in three sizes: 5mL, 10mL and 15mL. At the time of manufacture,
the product will have a 24-month shelf life.
Falcon s marketing and sales efforts will target wholesale distributors, retail
pharmacies, hospitals and managed care organizations, it will also communicate the
availability of brimonidine directly to ophthalmologists.
is the largest manufacturer and marketer of generic drugs for the eye and ear in the
United States. Alcon is the world s leading eye care company and has been dedicated
to the ophthalmic industry for more than 50 years. It develops, manufactures and markets
the widest selection of pharmaceuticals, surgical products, contact lens solutions and
other vision care products that treat diseases, disorders and other conditions of the eye.
Concerning Forward-Looking Statements. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be materially different from
any future results, performances or achievements expressed or implied by our
forward-looking statements. These statements reflect the views of our management as of the
date of this press release with respect to future events and are based on assumptions and
subject to risks and uncertainties. Given these uncertainties, you should not place undue
reliance on these forward-looking statements. Factors that might cause future results to
differ include, but are not limited to, the following: approval of drug applications by
the FDA, competition from other drugs, challenges inherent in new product manufacturing
and marketing, developments in legal cases and government regulation and legislation. You
should read this press release with the understanding that our actual future results may
be materially different from what we expect. Except to the extent required under the
federal securities laws and the rules and regulations promulgated by the Securities and
Exchange Commission, we undertake no obligation to publicly update or revise any of these
forward-looking statements, whether to reflect new information or future events or
circumstances or otherwise.
For information, contact:
MacHatton (Investor Relations)
News media and other inquiries: Mary Dulle (Public Relations)